title: Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.
abstract: In the light of current treatment developments for non-small cell lung cancer (NSCLC), the idea of a plastic cellular tumorigenic network bound by key paracrine signaling pathways mediating resistances to targeted therapies is brought forward. Based on a review of available preclinical and clinical data in NSCLC combinational approaches to address drivers of this network with marketed drugs are discussed. Five criteria for selecting drug combination regimens aiming at its disruption and thereby overcoming resistances are postulated.
authors.affiliation: Life Science Consulting, Hirschweg, Burgwedel, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Langhammer
authors.affiliation: Life Science Consulting, Hirschweg, Burgwedel, Germany.
authors.forename: Joachim
authors.initials: J
authors.lastname: Scheerer
mesh_terms: D000818:Animals; D015415:Biomarkers; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D003131:Combined Modality Therapy; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D015415:Biomarkers
keywords: EGFR; NSCLC; angiogenesis; targeted therapy